--AbbVie today announced that researchers will present new, long-term data supporting the efficacy and safety profile of RINVOQ ® from the SELECT-COMPARE, SELECT-PsA 1 and SELECT-AXIS 2 studies at the ...
Rinvoq is the first oral drug for moderate to severe Crohn’s disease — a chronic intestinal disorder — to be approved by the Food and Drug Administration. There is no cure for Crohn’s disease, and the ...
Safety was assessed through the cut-off date of 19 May, 2022, representing 534.4 patient-years of exposure to RINVOQ. 3 The study results support the efficacy and safety profile of RINVOQ in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results